BioSpace News Archive

MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, announced that it will host an analyst day webinar on EscharEx®, MediWound’s enzymatic debridement agent for chronic wounds, on Tuesday, March 30, 2021 at 10am Eastern Time.

Cash runway into the second half of 2023 Announced positive interim data from EQUATE study in aGVHD Multiple data and regulatory catalysts in 2021

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on March 31, 2021 at 8:00 AM Eastern Time to discuss results for its fourth quarter ended December 31, 2020.

- Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 - - NASH histology cohort topline data expected by YE21 - - Phase 2 SHTG trial (ENTRIGUE) expected to report topline data in 2H21

This twenty-first century has witnessed a significant increase in brain- and spine-related disorders such as cerebral palsy, acquired brain injury, spina bifida, spinal cord injuries, stroke, and polio.

Joint related issues are mostly recorded in geriatric and old aged peoples. Joint pain is caused due to tearing of synovial fluid in the joints due to injury or ageing.

A sedentary lifestyle, unhealthy eating habits, and growing stress levels are increasingly responsible for severe hair loss and damage, also known as alopecia.

Hyperlipidemia is a technical term for abnormal amounts of fats in the blood. The two noteworthy sorts of lipids found in the blood are triglycerides and cholesterol.

BrainStorm Cell Therapeutics Inc . (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company’s Phase 2 trial evaluating three repeated administrations of NurOwn® (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS).

Gamma Biosciences , a global life sciences company serving the advanced therapy market, today announced two additions to the senior management team of Astrea Bioseparations. Gabe Longoria will join Astrea as Chief Commercial Officer effective April 5 .